10-Q: Health In Tech Reports Q3 2026 Results, Faces Credit Loss Challenges

Health In Tech, Inc. reported a net loss of $7.1 million for Q3 2026, driven by increased credit loss provisions and a decline in revenues, while also securing new financing and announcing leadership transitions.

Summary

• Health In Tech, Inc. reported a net loss of $7.1 million for the third quarter of 2026, compared to a net income of $452,176 in the same period of 2025.
• Total revenues for the third quarter decreased by 22.4% to $6.6 million from $8.5 million in the prior year's quarter, primarily due to delays in new policy commencements following a carrier transition.
• The company recorded a significant provision for credit losses of $5.3 million in the third quarter of 2026, a substantial increase from a negligible amount in the prior year, largely due to assessments on deferred administrative surplus receivables, accounts receivable, and a loan receivable.
• Financing transaction costs of $0.8 million were incurred related to the Standby Equity Purchase Agreement (SEPA) and convertible notes.
• As of September 30, 2026, the company had $10.1 million in cash and cash equivalents.
• The company announced strategic leadership changes, including the appointment of Sanjay Shrestha as CEO and Tim Johnson as Executive Chairman.
• Stockholders approved an amendment to increase authorized shares and the equity incentive plan, and a new director, Tim Cortes, was elected.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant increases in credit loss provisions, a substantial net loss, and a decrease in revenues, despite efforts to secure new financing and strategic leadership changes.

Positives

• Secured $6.65 million in net proceeds from the first Pre-Paid Advance under the SEPA with Yorkville and $6.38 million from a PIPE financing.
• Launched HitRix, an AI-powered marketplace for large-group self-funded stop-loss insurance.
• Appointed Sanjay Shrestha as CEO and Tim Johnson as Executive Chairman, aiming to strengthen commercial execution and long-term strategy.
• Elected Tim Cortes to the Board of Directors, enhancing technology and engineering expertise.
• Stockholders approved an increase in authorized shares to 720 million and an amendment to the 2024 Equity Incentive Plan, increasing authorized shares for awards.
• Regained compliance with Nasdaq's independent director and audit committee requirements with the election of Tim Cortes.

Negatives

• Reported a net loss of $7.1 million for Q3 2026, a significant decline from a net income of $452,176 in Q3 2025.
• Total revenues decreased by 22.4% to $6.6 million in Q3 2026 compared to $8.5 million in Q3 2025.
• A substantial provision for credit losses of $5.3 million was recorded in Q3 2026, primarily impacting deferred administrative surplus receivables, accounts receivable, and a loan receivable.
• Cost of revenues increased as a percentage of revenue to 53.5% in Q3 2026 from 39.4% in Q3 2025.
• Sales and marketing expenses increased significantly as a percentage of revenue to 31.3% in Q3 2026 from 11.3% in Q3 2025.
• The company is at risk of delisting from Nasdaq due to its Class A common stock closing below the $1.00 minimum bid price requirement for over 30 consecutive business days.
• The company has outstanding convertible notes totaling $9.75 million as of September 30, 2026, with potential for further dilution.

Risks

• The company is at risk of delisting from The Nasdaq Capital Market if its Class A common stock does not close at $1.00 or more for at least ten consecutive business days by April 12, 2027.
• Substantial sales of Class A common stock into the market, either through conversion of convertible notes or under the SEPA, may cause the price of the stock to decline and dilute existing stockholders.
• The company's ability to meet its payment obligations under the SEPA could be impacted if cash flow from operations is insufficient, potentially leading to an event of default.
• The significant increase in credit loss provisions indicates potential issues with the collectability of receivables and loans, impacting financial health.
• Delays in policy commencements due to carrier transition have impacted revenue and may continue to affect future revenue recognition.
• The company's reliance on third-party service providers for cost of revenues presents a concentration risk.
• The company's ability to attract and retain customers and brokers is critical, and any disruption or negative perception could impact growth.

Future Outlook

The company revised its full-year 2026 revenue outlook to approximately $30 million, which is modestly below 2025 revenue, primarily due to delayed policy commencements. The company is focused on accelerating policy onboarding and improving conversion rates to drive revenue growth in 2027. The company expects to have sufficient liquidity for at least twelve months from the report date.

Management Comments

• The decrease in revenue primarily reflected delays in the commencement of certain new policies associated with the transition to a new carrier.
• The new carrier's different underwriting criteria and procedures required additional underwriting and approval before certain new policies could be bound and become effective.
• The portfolio transfers required additional administrative coordination among us, the carriers and the applicable third-party administrators, including reconciliations of premiums, enrollment information, claims and other amounts.
• We continue to pursue collection of the outstanding receivables and will reassess the allowance at each reporting date based on payments received, the aging of remaining balances, progress on outstanding reconciliations and other relevant facts and circumstances, adjusting the allowance as appropriate.
• The increase in sales and marketing expenses was primarily due to the increase in sales distribution fees with agencies, which drives revenue growth without the need for a large in-house sales force.
• The increase in research and development expenses was primarily attributable to our continued investment in technology development, driven by higher personnel costs as we expanded the development team.

Industry Context

StockSavvy.ai notes that Health In Tech operates in the competitive health insurance technology sector, facing challenges common to insurtech companies, including regulatory compliance, technological innovation, and managing complex financial instruments like convertible notes and equity purchase agreements. The company's focus on AI and automation aligns with industry trends, but the significant credit loss provisions highlight the inherent risks in managing receivables and loan portfolios within this sector.

Comparison to Industry Standards

• The company's revenue decline of 22.4% in Q3 2026 is concerning, especially when compared to the broader insurtech market which has seen growth in certain segments, though specific comparable data for companies with similar business models and challenges is limited.
• The significant increase in the provision for credit losses to $5.3 million in Q3 2026 is substantially higher than typical industry benchmarks for receivables and loan portfolios, indicating a specific issue with collectability for Health In Tech.
• The company's R&D expenses as a percentage of revenue (14.2% in Q3 2026) are substantial, reflecting a commitment to innovation that is common among technology-focused companies in the insurance sector, aiming to differentiate through automation and AI.
• The negative Adjusted EBITDA of ($3.9 million) in Q3 2026 is a key concern, as many mature insurtech companies aim for profitability or positive EBITDA. However, early-stage or growth-focused companies may prioritize market share and technology investment over immediate profitability.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not presently party to any legal proceedings the resolution of which it believes would have a material adverse effect on its business, prospects, financial condition, liquidity, results of operation, cash flows or capital levels.

Related Party Transactions

• The Company's Chief Executive Officer and Chief Financial Officer each contributed $35,714 in exchange for Class B common stock in HITChain, representing a 7.14% economic interest and 35.71% voting interest each.
• The Company entered into agreements with the Carrier (Roscommon Captive Management and Roscommon Insurance Company) to purchase rights to Deferred Administrative Surplus, with the Company's CEO and CFO having roles in the company.

Stakeholder Impact

• Shareholders: Potential dilution from future stock issuances under the SEPA and convertible notes; potential delisting from Nasdaq if bid price requirement is not met.
• Employees: Eligibility for equity awards under the amended 2024 Equity Incentive Plan; potential impact on compensation and benefits based on company performance.
• Creditors: The company has significant liabilities, including convertible notes, and its ability to meet obligations is crucial.
• Customers/Brokers: The launch of HitRix and the Three-Year Rate Stabilization Program aim to improve services and predictability, but revenue delays and credit loss issues could indirectly impact service continuity.

Next Steps

• Focus on accelerating policy onboarding and improving conversion rates to translate the pipeline into revenue growth in 2027.
• Monitor the closing bid price of Class A Common Stock and consider options, such as a reverse stock split, to regain compliance with Nasdaq's minimum bid price rule by April 12, 2027.
• Continue to pursue collection of outstanding receivables and reassess the allowance for credit losses at each reporting date.
• The company intends to monitor the closing bid price of its Class A Common Stock and consider available options if its Class A Common Stock does not trade at a level likely to result in the Company regaining compliance with Nasdaq's minimum bid price rule by April 12, 2027.

Key Dates

Recommendation

The company is facing significant financial headwinds, including a substantial net loss, declining revenues, and a dramatic increase in credit loss provisions. The ongoing risk of Nasdaq delisting due to the low stock price, coupled with the dilutive impact of recent financing activities (SEPA and convertible notes), presents considerable downside risk. While strategic leadership changes and new product launches are positive, they do not immediately offset the severe financial deterioration and operational challenges highlighted in this report.

Keywords

Equity Incentive Plan, Restricted Stock Award, Convertible Notes, Standby Equity Purchase Agreement, SEPA, Credit Losses, Revenue Recognition, Stock-Based Compensation